Evidence map›Paper›PMID 37591833›Full record

ArticleNature communications2023

Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study.

Adrienne Y L Chan, Andrew S C Yuen, Daniel H T Tsai, Wallis C Y Lau, Yogini H Jani, Yingfen Hsia, David P J Osborn, Joseph F Hayes, Frank M C Besag, Edward C C Lai and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Adrienne Y L Chan *Groningen Research Institute of Pharmacy, Unit of Pharmacotherapy, Epidemiology and Economics, University of Groningen, 72 9700, Groningen, The Netherlands.
Andrew S C Yuen *Research Department of Practice and Policy, School of Pharmacy, University College London, London, WC1H 9JP, UK.ORCID http://orcid.org/0009-0005-4850-566X
Daniel H T TsaiCentre for Neonatal and Paediatric Infection, St George's University of London, London, SW17 0RE, UK.ORCID http://orcid.org/0000-0003-2841-0338
Wallis C Y LauLaboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong SAR, China.ORCID http://orcid.org/0000-0003-2320-0470
Yogini H JaniResearch Department of Practice and Policy, School of Pharmacy, University College London, London, WC1H 9JP, UK.
Yingfen HsiaCentre for Neonatal and Paediatric Infection, St George's University of London, London, SW17 0RE, UK.
David P J OsbornDivision of Psychiatry, University College London, London, W1T 7BN, UK.
Joseph F HayesDivision of Psychiatry, University College London, London, W1T 7BN, UK.
Frank M C BesagResearch Department of Practice and Policy, School of Pharmacy, University College London, London, WC1H 9JP, UK.
Edward C C LaiSchool of Pharamcy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Li WeiResearch Department of Practice and Policy, School of Pharmacy, University College London, London, WC1H 9JP, UK.
Katja TaxisGroningen Research Institute of Pharmacy, Unit of Pharmacotherapy, Epidemiology and Economics, University of Groningen, 72 9700, Groningen, The Netherlands.
Ian C K WongLaboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong SAR, China. wongick@hku.hk.ORCID http://orcid.org/0000-0001-8242-0014
Kenneth K C ManLaboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong SAR, China. kenneth.man@ucl.ac.uk.ORCID http://orcid.org/0000-0001-8645-1942

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies raised concerns about the increasing use of gabapentinoids in different countries. With their potential for misuse and addiction, understanding the global consumption of gabapentinoids will offer us a platform to examine the need for any interventional policies. This longitudinal trend study utilised pharmaceutical sales data from 65 countries and regions across the world to evaluate the global trends in gabapentinoid consumption between 2008-2018. The multinational average annual percentage change of gabapentinoid consumption was +17.20%, increased from 4.17 defined daily dose per ten thousand inhabitants per day (DDD/TID) in 2008 to 18.26 DDD/TID in 2018. High-income countries had the highest pooled gabapentinoid consumption rate (39.92 DDD/TID) in 2018, which was more than six times higher than the lower-middle income countries (6.11 DDD/TID). The study shows that despite differences in healthcare system and culture, a consistent increase in gabapentinoid consumption is observed worldwide, with high-income countries remaining the largest consumers.

Indexed as

Behavior, AddictiveCommerceIncomeLongitudinal StudiesPolicy

Identifiers

PMID37591833
PMCPMC10435503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.